Get the Stockscreener App
21.52
0.37%
0.13
Catalyst Pharmaceuticals Inc stock is traded at $21.52, with a volume of 1.23M.
It is up +0.37% in the last 24 hours and up +5.45% over the past month.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
See More
Previous Close:
$21.39
Open:
$21.86
24h Volume:
1.23M
Relative Volume:
0.85
Market Cap:
$2.64B
Revenue:
$460.48M
Net Income/Loss:
$142.80M
P/E Ratio:
18.24
EPS:
1.18
Net Cash Flow:
$221.79M
1W Performance:
+0.14%
1M Performance:
+5.45%
6M Performance:
-8.13%
1Y Performance:
-10.28%
1-Day Range:
$21.31
$22.03
1-Week Range:
$20.66
$22.90
52-Week Range:
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Name
Catalyst Pharmaceuticals Inc
Sector
Industry
Phone
(305) 529-2522
Address
355 ALHAMBRA CIRCLE, CORAL GABLES
Compare CPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
21.56 | 2.63B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.25 | 103.89B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.74 | 69.11B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
441.70 | 58.49B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
869.83 | 52.62B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
191.97 | 40.46B | 447.02M | -1.18B | -906.14M | -6.1812 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Robert W. Baird | Outperform |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Mar-14-24 | Initiated | Citigroup | Buy |
| Mar-07-24 | Initiated | BofA Securities | Buy |
| Dec-21-23 | Initiated | Oppenheimer | Outperform |
| Aug-24-22 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-07-18 | Resumed | Piper Jaffray | Overweight |
| Oct-05-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-26-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Sep-30-14 | Reiterated | ROTH Capital | Buy |
| Sep-16-14 | Reiterated | ROTH Capital | Buy |
| Sep-15-14 | Reiterated | H.C. Wainwright | Buy |
| Oct-21-13 | Reiterated | Aegis Capital | Buy |
| Sep-24-13 | Initiated | Maxim Group | Buy |
| Sep-06-13 | Reiterated | Aegis Capital | Buy |
| Apr-18-13 | Initiated | Aegis Capital | Buy |
| Aug-27-12 | Upgrade | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| Oct-01-09 | Upgrade | Merriman | Sell → Neutral |
| May-29-09 | Downgrade | Hapoalim | Neutral → Underperform |
| May-29-09 | Downgrade | Merriman Curhan Ford | Buy → Sell |
| Dec-15-08 | Initiated | Merriman Curhan Ford | Buy |
| Nov-28-07 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jan-31-07 | Initiated | Stifel Nicolaus | Buy |
| Jan-05-07 | Initiated | First Albany | Buy |
View All
Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News
Why Catalyst Pharmaceuticals Inc. stock is considered a top pickJuly 2025 EndofMonth & Real-Time Market Sentiment Alerts - newser.com
Using portfolio simulators with Catalyst Pharmaceuticals Inc. includedTrade Analysis Report & Community Consensus Trade Alerts - newser.com
Will Catalyst Pharmaceuticals Inc. stock split again soonCEO Change & Daily Market Momentum Tracking - newser.com
Relative strength of Catalyst Pharmaceuticals Inc. in sector analysisEarnings Trend Report & Safe Capital Allocation Plans - newser.com
How rising interest rates impact Catalyst Pharmaceuticals Inc. stockTrade Exit Report & Low Drawdown Momentum Trade Ideas - newser.com
Momentum divergence signals in Catalyst Pharmaceuticals Inc. chart2025 Trade Ideas & Fast Entry Momentum Trade Alerts - newser.com
What analyst consensus says on Catalyst Pharmaceuticals Inc. stock2025 Trading Recap & Reliable Volume Spike Trade Alerts - newser.com
Published on: 2025-11-09 12:09:43 - newser.com
Is Catalyst Pharmaceuticals Inc. stock bottoming outTrade Risk Assessment & High Win Rate Trade Alerts - newser.com
Price momentum metrics for Catalyst Pharmaceuticals Inc. explainedJuly 2025 News Drivers & Safe Swing Trade Setup Alerts - newser.com
Is Catalyst Pharmaceuticals Inc CN2 a good long term investmentBlue Chip Stock Analysis & Best Stocks For Explosive Growth - earlytimes.in
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q3 2025 Earnings Call Transcript - Insider Monkey
Catalyst Pharmaceuticals Reports Strong Q3 2025 Earnings - TipRanks
CPRX: Citigroup Raises Price Target for Catalyst Pharmaceuticals - GuruFocus
Is Catalyst Pharmaceuticals’ (CPRX) Upgraded Revenue Forecast Signaling a Shift in Growth Prospects? - Yahoo Finance
Catalyst Pharma Reports Strong Q3 2025 Financial Results - MSN
Using Bollinger Bands to evaluate Catalyst Pharmaceuticals Inc.2025 Price Momentum & Weekly Hot Stock Watchlists - newser.com
Can Catalyst Pharmaceuticals Inc. hit a new high this monthM&A Rumor & AI Optimized Trade Strategies - newser.com
Published on: 2025-11-07 09:23:44 - newser.com
Catalyst Pharmaceuticals Rides Organic Growth To Record Results - Finimize
Catalyst Pharmaceuticals Inc (CPRX) Q3 2025 Earnings Call Highlights: Record Revenue and ... By GuruFocus - Investing.com Canada
What risks investors should watch in Catalyst Pharmaceuticals Inc. stockIPO Watch & Technical Entry and Exit Tips - newser.com
Is Catalyst Pharmaceuticals Inc. (CN2) stock a buy on weaknessJuly 2025 Big Picture & Safe Entry Momentum Tips - newser.com
Applying Elliott Wave Theory to Catalyst Pharmaceuticals Inc.July 2025 Movers & AI Based Buy and Sell Signals - newser.com
Will Catalyst Pharmaceuticals Inc. (CN2) stock keep high P E multiplesJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
Catalyst Pharmaceuticals Reports Strong Q3 2025 Results - TipRanks
Transcript : Catalyst Pharmaceuticals, Inc., Q3 2025 Earnings Call, Nov 06, 2025 - MarketScreener
Can Catalyst Pharmaceuticals Inc. (CN2) stock surprise with quarterly resultsInsider Selling & Real-Time Price Movement Reports - newser.com
Catalyst Pharmaceuticals (CPRX) Reports Strong Q3 2025 Results a - GuruFocus
Earnings call transcript: Catalyst Pharmaceuticals beats Q3 2025 expectations - Investing.com
Earnings call transcript: Catalyst Pharmaceuticals beats Q3 2025 expectations By Investing.com - Investing.com UK
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y - Yahoo Finance
Why Catalyst Pharmaceuticals Inc. stock is favored by pension fundsInsider Selling & Stepwise Trade Execution Plans - newser.com
Published on: 2025-11-06 04:52:28 - newser.com
Published on: 2025-11-06 01:22:44 - newser.com
Catalyst Pharmaceuticals Inc Stock (CPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Catalyst Pharmaceuticals Inc Stock (CPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Elsbernd Brian | Chief Compliance/Legal Officer |
Sep 08 '25 |
Sale |
20.30 |
30,000 |
609,000 |
271,039 |
0.09%
0.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):